Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation

Summary Background Asthma is an allergic airway inflammation‐driven disease that affects more than 300 million people world‐wide. Targeted therapies for asthma are largely lacking. Although asthma symptoms can be prevented from worsening, asthma development cannot be prevented. Cdc42 GTPase has been...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental allergy Vol. 49; no. 1; pp. 92 - 107
Main Authors Yang, Jun‐Qi, Kalim, Khalid W., Li, Yuan, Duan, Xin, Nguyen, Phuong, Khurana Hershey, Gurjit K., Kroner, John, Ruff, Brandy, Zhang, Li, Salomonis, Nathan, Rochman, Mark, Wen, Ting, Zheng, Yi, Guo, Fukun
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.01.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Background Asthma is an allergic airway inflammation‐driven disease that affects more than 300 million people world‐wide. Targeted therapies for asthma are largely lacking. Although asthma symptoms can be prevented from worsening, asthma development cannot be prevented. Cdc42 GTPase has been shown to regulate actin cytoskeleton, cell proliferation and survival. Objectives To investigate the role and targeting of Cdc42 in Th2 cell differentiation and Th2‐mediated allergic airway inflammation. Methods Post‐thymic Cdc42‐deficient mice were generated by crossing Cdc42flox/flox mice with dLckicre transgenic mice in which Cre expression is driven by distal Lck promoter. Effects of post‐thymic Cdc42 deletion and pharmacological targeting Cdc42 on Th2 cell differentiation were evaluated in vitro under Th2‐polarized culture conditions. Effects of post‐thymic Cdc42 deletion and pharmacological targeting Cdc42 on allergic airway inflammation were evaluated in ovalbumin‐ and/or house dust mite‐induced mouse models of asthma. Results Post‐thymic deletion of Cdc42 led to reduced peripheral CD8+ T cells and attenuated Th2 cell differentiation, with no effect on closely related Th1, Th17 and induced regulatory T (iTreg) cells. Post‐thymic Cdc42 deficiency ameliorated allergic airway inflammation. The selective inhibition of Th2 cell differentiation by post‐thymic deletion of Cdc42 was recapitulated by pharmacological targeting of Cdc42 with CASIN, a Cdc42 activity‐specific chemical inhibitor. CASIN also alleviated allergic airway inflammation. CASIN‐treated Cdc42‐deficient mice showed comparable allergic airway inflammation to vehicle‐treated Cdc42‐deficient mice, indicative of negligible off‐target effect of CASIN. CASIN had no effect on established allergic airway inflammation. Conclusion and Clinical Relevance Cdc42 is required for Th2 cell differentiation and allergic airway inflammation, and rational targeting Cdc42 may serve as a preventive but not therapeutic approach for asthma control.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
AUTHOR CONTRIBUTIONS
J. Q. Y. designed and performed research, analyzed data, and wrote the paper; K. W. K. performed research and analyzed data; Y.L. performed research and analyzed data; X. D. performed research; P.N. performed research; G.K.K.H. designed research, analyzed data, and contributed vital new reagents or analytical tools; J.K. performed research and analyzed data; B.R. performed research and analyzed data; L.Z. analyzed data; N.S. analyzed data; M.R. performed research; T.W. designed and performed research, analyzed data, and wrote the paper; M.E.R. designed research, contributed vital new reagents or analytical tools, and wrote the paper; Y. Z. designed research and contributed vital new reagents or analytical tools; F. G. designed research, analyzed data, contributed vital new reagents or analytical tools, and wrote the paper.
ISSN:0954-7894
1365-2222
DOI:10.1111/cea.13293